On the contrary, anti-PD-1 mAbs are more potent in formats that do not bind FcγRs, because this prevents cross-linking and agonistic activity or depletion of PD-1-expressing anti-tumor CD8+ T cells25,40. Here, CD8A is linked to neoplasm.